Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Cns-5161. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 3/20 | 0.54 |
| ▸ | GRIN3B known ✓ | O60391 | 3/20 | 0.54 |
| ▸ | GRIN1 known ✓ | Q05586 | 3/20 | 0.54 |
| ▸ | GRIN2A known ✓ | Q12879 | 3/20 | 0.54 |
| ▸ | GRIN2B known ✓ | Q13224 | 3/20 | 0.54 |
| ▸ | GRIN2C known ✓ | Q14957 | 3/20 | 0.54 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 3/20 | 0.54 |
| ▸ | SCN1A | P35498 | 2/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cns-5161 SCHEMBL29370312 | 1.00 | GRIN2D (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Cns-5161 SCHEMBL6420655 | 0.99 | GRIN2D (0.53) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2593943 | 0.96 | GRIN2D (0.51) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14126031 | 0.93 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7202740 | 0.92 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6724095 | 0.92 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6717121 | 0.92 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6720705 | 0.92 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL12123177 | 0.92 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL7208221 | 0.91 | GRIN2D (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | claimed |
| JP-2011526251-A | — | — | 2011-10-06 | — | — | JP | claimed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | claimed |
| EP-2310386-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2011-04-20 | — | — | EP | claimed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | claimed |
| EP-1883451-B1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2010-11-24 | — | — | EP | claimed |
| EP-2220075-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | Neuraxon, INC. (CA) | 2010-08-25 | — | — | EP | claimed |
| WO-2010000073-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-07 | — | — | WO | claimed |
| EP-2139886-A1 | QUINOLONE AND TETRAHYDROQUINOLINE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2010-01-06 | — | — | EP | claimed |
| EP-1888568-A4 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | NEURAXON INC (CA) | 2009-08-12 | — | — | EP | claimed |
| WO-2004039371-A2 | COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF NEUROPATHIC PAIN | PHARMACIA CORPORATION (US) | 2004-05-13 | — | — | WO | claimed |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | claimed |
| EP-0705100-B1 | THERAPEUTIC SUBSTITUTED GUANIDINES | CENES LTD (GB) | 2003-07-30 | — | — | EP | claimed |
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | WYETH | 2003-02-06 | — | — | US | claimed |
| US-6358696-B1 | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF ONE OR MORE SUBSTITUTED GUANIDINES TO TREAT DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2002-03-19 | — | — | US | claimed |
| US-6156741-A | Therapeutic substituted guanidines | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-12-05 | — | — | US | claimed |
| US-6153604-A | Therapeutic substituted guanidines | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-11-28 | — | — | US | claimed |
| US-6147063-A | NEUROTOXICITY | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-11-14 | — | — | US | claimed |
| WO-1999002145-A1 | COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-01-21 | — | — | WO | claimed |
| CN-1126434-A | Therapeutic substituted guanidines | CAMBRIDGE NEUROSCIENCE INC (US) | 1996-07-10 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | GRIN2D 530/4885GRIN3B 218/4885GRIN1 136/4885 |
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | RBP4, ALDH1A2, RBP1 | GRIN2D 3242/4885GRIN3B 1756/4885GRIN1 1760/4885 |
| US-20040082543-A1 | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | GRIN2A, GRIN2B, GRIN3A | GRIN2D 7/4885GRIN3B 6/4885GRIN1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.